https://www.selleckchem.com/pr....oducts/blasticidin-s
Despite unprecedented advances in the treatment of cancer through the use of immune checkpoint blockade (IC, responses are not universal and alternative strategies are needed to enhance responses to ICB. We have shown previously that a novel polyamine blocking therapy (PBT), consisting of cotreatment with α-difluoromethylornithine (DFMO) to block polyamine biosynthesis and a Trimer polyamine transport inhibitor, decreases myeloid-derived suppressor cells (MDSC) and M2-like tumor-associated macrophages (TAM). Both MDSCs and T
Like
Comment
Share
